第4章 癲癇治療藥的平台

第5章 癲癇的治療藥市場未來預測(今後6年份)

各地區市場趨勢

主要已開發國家

美國

歐洲主要5個國家

日本

加拿大

推動及阻礙市場要素

推動市場要素

阻礙市場要素

第6章 資本交易與策略性的企業整合

資本交易分析

研究開發(R&D):共同開發契約

研究開發(R&D):授權合約

第7章 附錄

圖表一覽

目錄

Product Code: GBIHC325MR

GBI Research has released its pharma research, "Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns", which provides in-depth analysis of epilepsy market within the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the epilepsy market in the major developed markets amounted to an estimated $3.4 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 3.9% to reach $4.5 billion by 2019. This modest growth is attributed to the recent approval of drugs with novel mechanisms of action that are expected to offer more therapeutic options to prescribers. The US takes major share of 55% of the global epilepsy market. In the US, three new anti-epileptic drugs have been approved since 2012: Trobalt, Aptiom, and Fycompa and another, brivaracetam, is expected also to be launched during the forecast period. Of these, Trobalt and Fycompa have novel mechanisms of action and improved safety and tolerability that elicited significant interest from prescribers. Continued uptake of second- and third-generation anti-epileptic drugs is also expected to contribute towards revenues in these eight regions. However, the epilepsy market could face the restricting influence of generic competition as a result of recent patent expiries in all major markets of two key branded drugs, Keppra and Lamictal.

A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target

Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action

Multi-scenario forecasts of the epilepsy market over the 2012-2019 period in the eight major developed markets

In-depth analysis of licensing and co-development agreements and an overview of key agreements that could impact growth trends

Key drivers and restraints that have had and are expected to have a significant impact upon the market

Abstract

The epilepsy therapeutics market value in the eight major countries - the US, Canada, France, Germany, Italy, Spain, the UK and Japan - will increase from $3.4 billion in 2012 to $4.5 billion by 2019, at a modest Compound Annual Growth Rate (CAGR) of 3.9%, says a new report from business intelligence provider GBI Research.

According to the report*, the US will grow at a higher CAGR of 4.8%, climbing from $1.9 billion in 2012 to $2.6 billion by 2019. Meanwhile, the five European countries and Canada will achieve a combined, smaller CAGR of 3.1% during the forecast period.

GBI Research attributes the anticipated market expansion to new Anti-Epileptic Drugs (AEDs) that have been approved during the last five years. However, further growth will be limited by the recent patent expiration of key AEDs, such as Keppra (levetiracetam) and Lamictal (lamotrigine).

"Second-generation AEDs, including levetiracetam, zonisamide and Vimpat (lacosamide), have signalled a shift in this trend in the last decade, with improved tolerability and safety through the use of new mechanisms of action. Recent approvals of Fycompa (perampanel) and Trobalt (retigabine) have continued this innovation by focusing on new molecular targets."

With most of the molecules being approved in the last few years, the current epilepsy pipeline is very weak. Phase III trials account for 18% of the overall pipeline, but the majority of these late-stage molecules are reformulations or line extensions of existing drugs.

"Furthermore, the recent epilepsy pipeline does not boast drugs with novel mechanisms of action, which are considered by most prescribers as an urgent need in epilepsy therapeutics today," Vulapalli concludes.

Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns

This report provides a comprehensive review of the epilepsy pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period. Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action is also included.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.